Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Overview
Determining where to allocate capital in the healthcare sector often involves choosing between established stability and aggressive growth. Both Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Co (NYSE:LLY) offer unique paths for investors.
Johnson & Johnson is a diversified healthcare leader with significant operations in medical technology and pharmaceuticals. Eli Lilly has recently emerged as a growth powerhouse focused on metabolic health and weight-loss treatments. Comparing these two giants helps you decide between a stable, diversified income play and a fast-growing pharmaceutical specialist.
Details
Johnson & Johnson operates as a leader among healthcare stocks through its Innovative Medicine and MedTech segments. Its portfolio includes blockbusters like Darzalex, which accounted for approximately 15% of revenue in 2025. The company is currently in the middle of a strategic shift, including a planned separation of its orthopedics business.
Source
Originally published at www.fool.com.